Reconsidering adjuvant and perioperative immune-checkpoint inhibition: de-escalation, expansion and personalization - PubMed
4 days ago
- #cancer treatment
- #biomarkers
- #immune-checkpoint inhibition
- Anti-PD-L1 antibodies are increasingly used in early-stage cancer treatment, including adjuvant and neoadjuvant settings.
- Earlier administration of these agents may reduce metastatic risk and improve overall survival, though benefits in adjuvant settings are not yet clear in all tumor types.
- The review explores optimal use of anti-PD-L1 antibodies in adjuvant and perioperative settings, focusing on melanoma, renal cell carcinoma, and non-small-cell lung cancer.
- De-escalation strategies include shortening treatment duration or deferring therapy until recurrence, potentially allowing for combination therapies.
- Expansion of specific indications could lead to more effective combinations or use in biomarker-defined high-risk early-stage patients.
- Neoadjuvant or perioperative use might be more effective than adjuvant use in certain cancers, with potential for therapy personalization guided by biomarkers like circulating tumor DNA.